Calytrix Bio Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • M&A
  • (Announced)

  • Latest Deal Amount
  • $1.5B

  • Investors
  • 3

Calytrix Bio General Information

Description

Developer of precision biotechnology therapies intended to treat myeloproliferative neoplasms. The company offers a novel biparatopic antibody designed for pan-mutant activity against mutant calreticulin, providing patients with essential thrombocythemia and myelofibrosis with disease-modifying treatments that target underlying genetic drivers while preserving healthy hematopoiesis.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 20 William Street
  • Suite 270
  • Wellesley Hills, MA 02481
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 20 William Street
  • Suite 270
  • Wellesley Hills, MA 02481
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Calytrix Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 16-Nov-2026 $1.5B Announced Startup
2. Early Stage VC (Series B) Completed Startup
1. Early Stage VC (Series A) Completed Startup
To view Calytrix Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Calytrix Bio Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Avoro Ventures Corporate Venture Capital Minority
JPMorgan Life Sciences Private Capital Venture Capital Minority
Westlake Village BioPartners Venture Capital Minority
To view Calytrix Bio’s complete investors history, request access »

Calytrix Bio FAQs

  • When was Calytrix Bio founded?

    Calytrix Bio was founded in 2025.

  • Where is Calytrix Bio headquartered?

    Calytrix Bio is headquartered in Wellesley Hills, MA.

  • What industry is Calytrix Bio in?

    Calytrix Bio’s primary industry is Drug Discovery.

  • Is Calytrix Bio a private or public company?

    Calytrix Bio is a Private company.

  • What is the current valuation of Calytrix Bio?

    The current valuation of Calytrix Bio is .

  • What is Calytrix Bio’s current revenue?

    The current revenue for Calytrix Bio is .

  • Who are Calytrix Bio’s investors?

    Avoro Ventures, JPMorgan Life Sciences Private Capital, and Westlake Village BioPartners have invested in Calytrix Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process